Sort by
Refine Your Search
-
the leadership of Erik Wennerberg , we are seeking to appoint a Postdoctoral Training Fellow to join the Radiation-enhanced Immunotherapy Group to study how radiotherapy alters the tumour microenvironment in solid
-
(NETs), whilst rare, are the exemplar cancer type investigated here as they are hard to treat. External beam radiotherapy and molecular radionuclide therapy in the form of 177Lu-DOTATATE have enhanced
-
resection followed by radiotherapy and chemotherapy. Injectable, self-healing and mechanically tuneable hydrogels have been designed and developed within the Scherman research group to match the mechanical
-
investigated here as they are hard to treat. External beam radiotherapy and molecular radionuclide therapy in the form of 177Lu-DOTATATE have enhanced survival for some NET patients, but the long-term outlook
-
statisticians, epidemiologists, oncologists, a surgeon, a radiotherapy physicist, and DPhil students. To be considered you will hold a PhD in statistics or a closely related field. You will have experience
-
contribute to ground-breaking research aimed at enhancing the effectiveness of radiotherapy treatments. Our focus lies in developing innovative approaches to sensitize tumor cells to radiotherapy, with
-
The Research Assistant will be based within the radiotherapy physics service in the NI Cancer Centre and participate in scientific research activities in radiation oncology physics. Working in close
-
of this project is to develop anticancer molecularly targeted radiotherapy agents (theranostics) for the imaging and treatment of cancer. The focus of the project will be on specific organelle targeting with
-
the radiotherapy physics service in the NI Cancer Centre and participate in scientific research activities in radiation oncology physics. Working in close collaboration with physics, clinical and radiographic staff
-
to tangible improvements in patient survival, which has improved little over the last 40 years. Most patients receive surgical resection followed by DNA damaging radiotherapy and temozolomide